Targeted Therapy Privately held biotech focusing on tumor-targeted therapy using porphyrin metabolite activation with low-intensity ultrasound to achieve localized effects, presenting a clear value proposition for oncology-focused collaborations and licensing deals.

Lead Program Focus Lead program targets glioblastoma, a high-need area with strong interest from major oncology players and research institutions, signaling potential partnerships with neuro-oncology centers and regulatory-aligned clinical collaboration opportunities.

Funding Momentum Recent Series B funding of 52M plus prior Series A of 16M indicates growing investor confidence and credibility, suggesting readiness for strategic partnerships, co-development opportunities, and larger-scale pilot programs.

Clinical Progress Advancement in a novel SDT platform and PoMA approach positions the company as a differentiator in non-invasive, drug-centered activation, creating opportunities to engage with contract research organizations (CROs) and academic collaborators for trial support.

Market Readiness Revenue activity in the low millions and a small to mid-sized team imply lean operations with high partner leverage potential for large medical device, imaging, or ultrasound technology firms seeking integration with tumor-targeting therapeutics.